

P21313.A02



Receipt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : S. SHIBAMURA et al

Attention : Office of Initial Patent Examination's
Customer Service Center

Appl. No. : 09/920,805

Group Art Unit : 1642

Filed : August 3, 2001

Examiner : Unknown

For : COMPOSITION FOR IMMUNOHISTOCHEMICAL STAINING

REQUEST FOR CORRECTION OF FILING RECEIPT

Commissioner of Patents and Trademarks
Washington, D.C. 20231

RECEIVED
SEP 25 2001
TECH CENTER 1600/2900

Sir:

The attorney docket number of the above-identified application, as it appears on the Official Filing Receipt, is incorrect. The attorney docket number should read **P21313**, not P21323 as it appears on the Filing Receipt. Also attached, please find a copy of the incorrect Official Filing Receipt with the requested change noted thereon.

Please correct the attorney docket number of the above-identified application to read as follows:

P21313


instead of:

P21323

P21313.A02

and forward a corrected copy of the Filing Receipt to the undersigned.

Respectfully submitted,
S. SHIBAMURA et al


Arnold Turk
Reg. No. 33,094 Reg No 45,305

September 12, 2001
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/920,805	08/03/2001	1642	862	P21313 P21313	2	24	4


CONFIRMATION NO. 7834

FILING RECEIPT



OC000000006478130

7055
GREENBLUM & BERNSTEIN, P.L.C.
1941 ROLAND CLARKE PLACE
ALEXANDRIA, VA 20191



Date Mailed: 08/28/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Seiichi Shibamura, Tokyo, JAPAN;
Susumu Ito, Tokushima, JAPAN;
Kazuhiro Takesako, Kumamoto, JAPAN;
Irimura Tatsuro, Tokyo, JAPAN;

Assignment For Published Patent Application

DAIICHI PURE CHEMICAL CO., LTD., Tokyo, JAPAN;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/147,839 06/17/1999 ABN
WHICH IS A 371 OF PCT/JP97/03306 09/18/1997

Foreign Applications

JAPAN 8-246782 09/19/1996
JAPAN 8-347886 12/26/1996
JAPAN 9-45516 02/28/1997

If Required, Foreign Filing License Granted 08/27/2001

Projected Publication Date: 12/06/2001

Non-Publication Request: No

Early Publication Request: No

RECEIVED
AUG 29 2001
GREENBLUM & BERNSTEIN, P.L.C.

RECEIVED
SEP 25 2001
TECH CENTER 1600/2900

COPY

Title

Composition for immunohistochemical staining

Preliminary Class

435

Data entry by : SOUNANNARATH, LINDA

Team : OIPE

Date: 08/28/2001

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231